logo

For the Inventor, By the Inventor

Anjoh, Japan

Hideaki Inagaki

This inventor holds 7 USPTO granted patents and 1 published patent application. Top assignees: Telik, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Other. Active years: 2003-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideaki Inagaki. Retrieved from https://idiyas.com/inventor/hideaki-inagaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 14.3

Average Co-Inventor Count = 13.5

ph-index = 3

Forward Citations = 32(Granted Patents)


Location History:

  • Inabe, JP (2005)
  • Anjoh, JP (2003 - 2007)

Company Filing History:

goldMedal4 out of 37 
 
Telik, Inc.
 patents
silverMedal3 out of 108 
 
Sanwa Kagaku Kenkyusho Co., Ltd.
 patents
bronzeMedal3 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 2003-2007

Loading Chart...
7 patents (USPTO):Explore Patents
1. 7297696 - Antagonists of MCP-1 function and methods of use thereof (2007-11-20),
2. 6998407 - Antagonists of MCP-1 function and methods of use thereof (2006-02-14),
3. 6992086 - Antagonists of MCP-1 function and methods of use thereof (2006-01-31),
4. 6962926 - Antagonist of MCP-1 function, and compositions and methods of use thereof (2005-11-08),
5. 6809113 - Antagonists of MCP-1 function and methods of use thereof (2004-10-26),
6. 6677365 - Antagonists of MCP-1 function and methods of use thereof (2004-01-13),
7. 6670364 - Antagonists of MCP-1 function and methods of use thereof (2003-12-30),

Title: The Innovations of Hideaki Inagaki

Introduction

Hideaki Inagaki is a notable inventor based in Anjoh, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target inflammatory and autoimmune diseases. With a total of seven patents to his name, Inagaki's work has the potential to impact many lives.

Latest Patents

Inagaki's latest patents include innovative compounds that act as antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function. These compounds are designed for the prevention or treatment of various chronic or acute inflammatory and autoimmune diseases. Conditions such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection are specifically targeted by these pharmaceutical compositions. The methods of treatment and processes for preparing these compounds are also detailed in his patents.

Career Highlights

Throughout his career, Inagaki has worked with reputable companies such as Telik, Inc. and Sanwa Kagaku Kenkyusho Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.

Collaborations

Inagaki has collaborated with professionals like Edgardo Laborde and Louise Robinson. These partnerships have likely enhanced his research and innovation efforts.

Conclusion

Hideaki Inagaki's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to addressing significant health challenges. His work continues to pave the way for advancements in the treatment of inflammatory and autoimmune diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…